# US 2026/0234639 A1 · Compounds and Methods for Reducing KCNT1 Expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234639 A1
- Document ID: US20260234639A1
- Status: Published application
- Kind: A1
- Application number: 19/652,847
- Filed: 2026-04-20
- Published: 2026-08-13
- Earliest claimed: 2020-06-25
- Assignees: Ionis Pharmaceuticals, Inc.
- Applicants: Ionis Pharmaceuticals, Inc.
- Inventors: Paymaan Jafar-nejad
- Web page: https://patentgrep.com/patent/US20260234639A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain instances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurological condition. Such symptoms and hallmarks include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods, and pharmaceutical compositions are epilepsy of infancy with migrating focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome, and Ohtahara syndrome.

## Claims

### Claim 1

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to an equal length portion of a KCNT1 nucleic acid, and wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage.

### Claim 2

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 2940-3016.

### Claim 3

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
an equal length portion of nucleobases 55245-55287 of SEQ ID NO: 2, or
an equal length portion of nucleobases 87550-87576 of SEQ ID NO: 2.

### Claim 4

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 contiguous nucleobases complementary to:
SEQ ID NOs: 2940, 2951, 2952, 2953, 2954, 2955, 2956, 2957, 2958, 2959, 2960, 2961, 2963, 2987, 2998, or 2999; or
SEQ ID NOs: 2981, 2982, 2995, or 3012.

### Claim 5

An oligomeric compound comprising a modified oligonucleotide consisting of 12 to 50 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases SEQ ID NOs: 2957, 2958, 2966, 2967, 2968, or 2971.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The oligomeric compound of any of claims 1-5, wherein the modified oligonucleotide has a nucleobase sequence that is at least 80%, 85%, 90%, 95%, or 100% complementary to an equal length portion of a nucleobase sequence selected from SEQ ID NOs: 1-3 when measured across the entire nucleobase sequence of the modified oligonucleotide.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The oligomeric compound of any of claims 1-6, comprising at least one modified nucleoside comprising a modified sugar moiety.

### Claim 8 (depends on 7)

The oligomeric compound of claim 7, wherein the modified sugar moiety comprises a bicyclic sugar moiety.

### Claim 9 (depends on 8)

The oligomeric compound of claim 8, wherein the bicyclic sugar moiety comprises a 2′-4′ bridge selected from —O—CH2—; and —O—CH(CH3)—.

### Claim 10 (depends on 7)

The oligomeric compound of claim 7, wherein the modified sugar moiety comprises a non-bicyclic modified sugar moiety.

### Claim 11 (depends on 10)

The oligomeric compound of claim 10, wherein the non-bicyclic modified sugar moiety comprises a 2′-MOE sugar moiety or 2′-OMe sugar moiety.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

The oligomeric compound of any of claims 1-6, comprising at least one modified nucleoside comprising a sugar surrogate.

### Claim 13 (depends on 12)

The oligomeric compound of claim 12, wherein the sugar surrogate is selected from morpholino and PNA.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The oligomeric compound of any of claims 1-13, wherein the modified oligonucleotide has a sugar motif comprising:
a 5′-region consisting of 1-5 linked 5′-region nucleosides;
a central region consisting of 6-10 linked central region nucleosides; and
a 3′-region consisting of 1-5 linked 3′-region nucleosides; wherein
each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises an unmodified 2′-deoxyribosyl sugar moiety.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The oligomeric compound of any of claims 1-13, wherein the modified oligonucleotide has a sugar motif comprising: a 5′ region consisting of 4 linked 5′ region nucleosides and a 3′ region consisting of 6 linked 3′ region nucleosides, and a central region consisting of 10 linked central region nucleosides, wherein each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises an unmodified 2′-deoxyribosyl sugar moiety and wherein the modified sugar moiety is a 2′-MOE modified sugar moiety.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The oligomeric compound of any of claims 1-13, wherein the modified oligonucleotide has a sugar motif comprising a 5′ region consisting of 6 linked 5′ region nucleosides and a 3′ region consisting of 4 linked 3′ region nucleosides, and a central region consisting of 10 linked central region nucleosides, wherein each of the 5′-region nucleosides and each of the 3′-region nucleosides comprises a modified sugar moiety and each of the central region nucleosides comprises an unmodified 2′-deoxyribosyl sugar moiety and wherein the modified sugar moiety is a 2′-MOE modified sugar moiety.

### Claim 17 (depends on 14)

The oligomeric compound of claim 14, wherein the 5′ region consists of 5 linked 5′ region nucleosides and the 3′ region consist of 5 linked 3′ region nucleosides, and the central region consists of 10 linked central region nucleosides, wherein the modified sugar moiety is a 2′-MOE modified sugar moiety.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The oligomeric compound of any of claims 1-17, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 19 (depends on 18)

The oligomeric compound of claim 18, wherein each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.

### Claim 20 (depends on 18, 19)

The oligomeric compound of claim 18 or 19, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 21 (depends on 18, 20)

The oligomeric compound of claim 18 or 20, wherein the modified oligonucleotide comprises at least one phosphodiester internucleoside linkage.

### Claim 22 (depends on 18, 20, 21)

The oligomeric compound of any of claims 18, 20 or 21, wherein each internucleoside linkage is independently selected from a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The oligomeric compound of any of claims 1-22, wherein the modified oligonucleotide comprises at least one modified nucleobase.

### Claim 24 (depends on 23)

The oligomeric compound of claim 23, wherein the modified nucleobase is a 5-methyl cytosine.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The oligomeric compound of any of claims 1-24, wherein the modified oligonucleotide consists of 12-30, 12-22, 12-20, 14-20, 15-25, 16-20, 18-22 or 18-20 linked nucleosides.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The oligomeric compound of any of claims 1-25, wherein the modified oligonucleotide consists of 20 linked nucleosides.

### Claim 27 (depends on 26)

The oligomeric compound of claim 26, wherein the modified oligonucleotide has the internucleoside linkage motif soooossssssssssooss, wherein “s” represents a phosphorothioate internucleoside linkage and “o” represents a phosphodiester internucleoside linkage.

### Claim 28

An oligomeric compound comprising a modified oligonucleotide according to the following formula: Tes Teo Geo Teo mCeo Tds Tds Tds Tds mCds Tds Tds Tds mCds Ads Aeo mCeo Tes Ges Ae (SEQ ID NO: 2958), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 29

An oligomeric compound comprising a modified oligonucleotide according to the following formula: Tes Geo Teo mCeo Tds Tds Tds Tds mCds Tds Tds Tds mCds Ads Aeo mCeo Teo Ges Aes Te (SEQ ID NO: 2957), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 30

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes Teo mCeo Aeo Teo Tds Tds mCds Ads mCds Tds mCds mCds Gds Gds mCeo Aeo Ges Ges mCe (SEQ ID NO: 2966), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 31

An oligomeric compound comprising a modified oligonucleotide according to the following formula: Tes Geo mCeo Aeo mCeo Aeo Gds Ads Tds mCds Tds Tds mCds Ads Tds Ads Geo mCes Aes Ae (SEQ ID NO: 2362), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 32

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes mCeo Aeo Teo Tds Tds Ads Ads Tds Ads Gds Ads Ads Gds Teo Teo Teo mCes mCes Ae (SEQ ID NO: 2968), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 33

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes Aeo Teo mCeo mCeo Aeo Tds Tds Tds Ads Ads Tds Ads Gds Ads Ads Geo Tes Tes Te (SEQ ID NO: 2971), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 34

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes mCeo Aeo mCeo mCeo Ads Gds mCds Tds mCds Ads Tds Tds Tds mCds Aeo mCeo Tes mCes mCe (SEQ ID NO: 2967), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 35

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes mCeo Aeo mCeo mCds Ads Gds mCds Tds mCds Ads Tds Tds Tds mCeo Aeo mCeo Tes mCes mCe (SEQ ID NO: 2967), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 36

An oligomeric compound comprising a modified oligonucleotide according to the following formula: mCes mCeo Aeo Teo Teo Tds Ads Ads Tds Ads Gds Ads Ads Gds Tds Teo Teo mCes mCes Ae (SEQ ID NO: 2968), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 37

An oligomeric compound comprising a modified oligonucleotide according to the following formula: Tes Geo mCeo Aeo Teo mCeo mCds Ads Tds Tds Tds Ads Ads Tds Ads Gds Aeo Aes Ges Te (SEQ ID NO: 1162), wherein,
A=an adenine,
mC=a 5′-methylcytosine
G=a guanine,
T=a thymine,
e=a 2′-O-methoxyethylribose modified sugar
d=a 2′-deoxyribose sugar,
s=a phosphorothioate internucleoside linkage, and
o=a phosphodiester internucleoside linkage.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The oligomeric compound of any of claims 1-37, consisting of the modified oligonucleotide.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The oligomeric compound of any of claims 1-37, comprising a conjugate group comprising a conjugate moiety and a conjugate linker.

### Claim 40 (depends on 39)

The oligomeric compound of claim 39, wherein the conjugate group comprises a GalNAc cluster comprising 1-3 GalNAc ligands.

### Claim 41 (depends on 39, 40)

The oligomeric compound of claim 39 or 40, wherein the conjugate linker consists of a single bond.

### Claim 42 (depends on 39)

The oligomeric compound of claim 39, wherein the conjugate linker is cleavable.

### Claim 43 (depends on 42)

The oligomeric compound of claim 42, wherein the conjugate linker comprises 1-3 linker-nucleosides.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The oligomeric compound of any of claims 39-43, wherein the conjugate group is attached to the modified oligonucleotide at the 5′-end of the modified oligonucleotide.

### Claim 45 (depends on 39, 40, 41, 42, 43)

The oligomeric compound of any of claims 39-43, wherein the conjugate group is attached to the modified oligonucleotide at the 3′-end of the modified oligonucleotide.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The oligomeric compound of any of claims 1-45, comprising a terminal group.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The oligomeric compound of any of claims 1-46, wherein the oligomeric compound is a singled-stranded oligomeric compound.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45)

The oligomeric compound of any of claims 1-42, 44 or 45, wherein the oligomeric compound does not comprise linker-nucleosides.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The oligomeric compound of any of claims 1-48, wherein the modified oligonucleotide of the oligomeric compound is a salt, and wherein the salt is a sodium salt or a potassium salt.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49)

An oligomeric duplex comprising an oligomeric compound of any of claims 1-46, 48 or 49.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

An antisense compound comprising or consisting of an oligomeric compound of any of claims 1-49 or an oligomeric duplex of claim 50.
or a salt thereof.

### Claim 53 (depends on 52)

The modified oligonucleotide of claim 52, which is the sodium salt or the potassium salt.

### Claim 54

A modified oligonucleotide according to the following chemical structure:

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A pharmaceutical composition comprising the oligomeric compound of any of claims 1-49, or the oligomeric duplex of claim 50, or the antisense compound of claim 51, or the modified oligonucleotide of any of claims 52-54; and a pharmaceutically acceptable carrier or diluent.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid or phosphate buffered saline (PBS).

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and artificial cerebrospinal fluid.

### Claim 58 (depends on 56)

The pharmaceutical composition of claim 56, wherein the pharmaceutical composition consists essentially of the modified oligonucleotide and PBS.

### Claim 59 (depends on 55, 56, 57, 58)

A method comprising administering to a subject a pharmaceutical composition of any of claims 55-58.

### Claim 60 (depends on 55, 56, 57, 58)

A method of treating a neurological condition comprising administering to an individual having or at risk for developing the neurological condition a therapeutically effective amount of the pharmaceutical composition according to any of claims 55-58; and thereby treating the neurological condition.

### Claim 61 (depends on 55, 56, 57, 58)

A method of reducing KCNT1 RNA or KCNT1 protein in the central nervous system of an individual having or at risk for developing a neurological condition comprising administering a therapeutically effective amount of the pharmaceutical composition according to any of claims 55-58; and thereby reducing KCNT1 RNA or KCNT1 protein in the central nervous system.

### Claim 62 (depends on 60, 61)

The method of claim 60 or 61, wherein the neurological condition comprises encephalopathy.

### Claim 63 (depends on 60, 61)

The method of claim 60 or 61, wherein the neurological condition comprises epilepsy.

### Claim 64 (depends on 60, 61)

The method of claim 60 or 61, wherein the neurological condition comprises infantile epilepsy.

### Claim 65 (depends on 64)

The method of claim 64, wherein the infantile epilepsy is epilepsy of infancy with migrating focal seizures (EIMFS).

### Claim 66 (depends on 60, 61)

The method of claim 60 or 61, wherein the neurological condition is autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).

### Claim 67 (depends on 59, 60, 61, 62, 63, 64, 65, 66)

The method of any of claims 59-66, wherein the administering is by intrathecal administration.

### Claim 68 (depends on 60, 61, 62, 63, 64, 65, 66, 67)

The method of any of claims 60-67, wherein at least one symptom or hallmark of the neurological condition is ameliorated.

### Claim 69 (depends on 68)

The method of claim 68, wherein the symptom or hallmark is selected from seizure, brain damage, demyelination, hypotonia, microcephaly, depression, anxiety, or impaired cognitive function.

### Claim 70 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any of claims 59-69, wherein the method prevents or slows disease regression.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A method of reducing KCNT1 RNA in a cell comprising contacting the cell with an oligomeric compound according to any of claims 1-49, or an oligomeric duplex according to claim 50, or an antisense compound according to claim 51, or a modified oligonucleotide of any of claims 52-54; thereby reducing KCNT1 RNA in the cell.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A method of reducing KCNT1 protein in a cell comprising contacting the cell with the oligomeric compound according to any of claims 1-49, or the oligomeric duplex according to claim 50, or the antisense compound according to claim 51, or the modified oligonucleotide of any of claims 52-54; thereby reducing KCNT1 protein in the cell.
